Meanwhile, many new BH3 mimetics of the Bcl-2 family have emerged in recent years, such as selective Mcl-1 antagonists, which have been observed having good curative effects in treatment of AML 44, but there is also the problem of acquired resistance. The gene discussed is BCL2; the disease is acute myeloid leukemia.